Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 6,699 | 6,750 | 7,028 | 27,813 | 1,153 |
| Cost of Goods | 300 | -567 | 3,261 | 636 | N/A |
| Gross Profit | 6,399 | 7,317 | 3,768 | 27,178 | 1,153 |
| Operating Expenses | 79,542 | 22,888 | 39,407 | 13,923 | 17,233 |
| Operating Income | -72,843 | -16,137 | -35,379 | 13,890 | -16,080 |
| Interest Expense | 0 | 0 | 0 | 24 | 464 |
| Other Income | 5,666 | 147 | 55 | -30 | 73 |
| Pre-tax Income | -67,177 | -15,990 | -35,324 | 13,836 | -16,472 |
| Income Tax | -2,793 | 280 | -50 | 1,967 | N/A |
| Net Income Continuous | -64,384 | -16,271 | -35,274 | 11,870 | -16,472 |
| Net Income Discontinuous | 884 | 198 | -4,779 | N/A | N/A |
| Net Income | $-63,500 | $-16,073 | $-40,053 | $11,870 | $-16,472 |
| EPS Basic Total Ops | -2,458.13 | -800.32 | -3,429.94 | 1,200.48 | -5,345.00 |
| EPS Basic Continuous Ops | -2,486.71 | -800.32 | -3,029.78 | 1,842.88 | -5,331.65 |
| EPS Basic Discontinuous Ops | 28.58 | 0.00 | -400.16 | N/A | N/A |
| EPS Diluted Total Ops | -12,347.80 | -4,030.18 | -3,429.94 | 1,200.48 | -5,345.00 |
| EPS Diluted Continuous Ops | -12,519.29 | -4,058.77 | -3,029.78 | 1,809.00 | -5,331.65 |
| EPS Diluted Discontinuous Ops | 171.50 | 28.58 | -400.16 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -1,629.22 | -857.49 | N/A | N/A | N/A |
| EBITDA(a) | $-71,000 | $-10,698 | $-28,661 | $14,453 | $-16,053 |